Avadel Pharma (AVDL) Announces FDA Approval of LUMRYZ …
1 day ago · LUMRYZ is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy -- Granted Orphan Drug ...
Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ …
1 day ago · DUBLIN, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that the U.S ...
Avadel Pharmaceuticals PLC (AVDL) Q2 2024 Earnings Call …
Oct 9, 2024 · Avadel Pharmaceuticals PLC (NASDAQ:AVDL) reported a significant increase in net revenue, reaching $41.5 million in the second quarter of 2024, driven by strong patient demand for LUMRYZ. The ...
Avadel wins FDA approval for narcolepsy drug Lumryz in children
11 hours ago · The company agreed to pay $20m in civil and criminal penalties over a period of five years. "Avadel wins FDA approval for narcolepsy drug Lumryz in children" was originally created and published ...
Avadel Pharmaceuticals plc (AVDL) Stock Price, Quote, News
Oct 11, 2024 · Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. A high-level overview of Avadel Pharmaceuticals plc (AVDL) stock.
Avadel Pharmaceuticals plc (AVDL) - Stock Analysis
1 day ago · Get a real-time Avadel Pharmaceuticals plc (AVDL) stock price quote with breaking news, financials, statistics, charts and more.
Press Releases - Avadel Pharmaceuticals PLC
Avadel Pharmaceuticals Announces Publication in Clinical Therapeutics of Data Highlighting Weight Loss in People with Narcolepsy Treated with LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension. DUBLIN , Aug. 20, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biophar... 08/08/24.
Avadel Pharmaceuticals Announces Final FDA Approval of
May 1, 2023 · Avadel Pharmaceuticals Announces Final FDA Approval of LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension as the First and Only Once-at-Bedtime Oxybate for Cataplexy or Excessive ...
Avadel Obtains FDA Nod for Label Expansion of Narcolepsy Drug …
1 day ago · Label Expansion of AVDL’s Lumryz. Lumryz is a once-at-bedtime formulation extended-release sodium oxybate. It was first approved by the FDA on May 1, 2023, for the treatment of cataplexy or EDS ...
Avadel Pharmaceuticals PLC (AVDL) Stock Price Today - WSJ
View the latest Avadel Pharmaceuticals PLC (AVDL) stock price, news, historical charts, analyst ratings and financial information from WSJ.
- Some results have been removed